Murine pharmacokinetics of rifapentine delivered as an inhalable dry powder

International Journal of Antimicrobial Agents

Volumn 45, Issue 3, 2015, Pages 319-323

  Chan, John G Y ^a,b   Tyne, Anneliese S ^c,d   Pang, Angel ^c   McLachlan, Andrew J ^d,e   Perera, Vidya ^f,g   Chan, Joseph C Y ^a   Britton, Warwick J ^c,d   Chan, Hak Kim ^d   Duke, Colin C ^d   Young, Paul M ^a   Traini, Daniela ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b JHL Biotech Inc   (Taiwan)

^c CENTENARY INSTITUTE   (Australia)

^d UNIVERSITY OF SYDNEY   (Australia)

^e ANZAC Research Institute   (Australia)

^f NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^g UNIVERSITY AT BUFFALO   (United States)

Author keywords

Aerosol delivery; Granuloma; Inhaled dry powder; Rifapentine; Tuberculosis

Indexed keywords

RIFAPENTINE; AEROSOL; POWDER; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG TISSUE LEVEL; DRY POWDER; FEMALE; LUNG LAVAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; ADMINISTRATION AND DOSAGE; AEROSOL; ANALOGS AND DERIVATIVES; ANIMAL; ANIMAL MODEL; BAGG ALBINO MOUSE; CHEMISTRY; INHALATIONAL DRUG ADMINISTRATION; LUNG; PLASMA; POWDER; STATISTICAL MODEL;

ADMINISTRATION, INHALATION; AEROSOLS; ANIMALS; ANTIBIOTICS, ANTITUBERCULAR; BRONCHOALVEOLAR LAVAGE FLUID; FEMALE; LUNG; MICE, INBRED BALB C; MODELS, ANIMAL; MODELS, STATISTICAL; PLASMA; POWDERS; RIFAMPIN;

EID: 84923686713     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2014.11.009     Document Type: Article

References (13)

1. World Health Organisation Global tuberculosis control 2011. Geneva, Switzerland: WHO; 2011.
2. D.P. Holland, G.D. Sanders, C.D. Hamilton, and J.E. Stout Potential economic viability of two proposed rifapentine-based regimens for treatment of latent tuberculosis infection PLoS One 6 2011 e22276
3. T. Zhang, M. Zhang, I.M. Rosenthal, J.H. Grosset, and E.L. Nuermberger Short-course therapy with daily rifapentine in a murine model of latent tuberculosis infection Am J Respir Crit Care Med 180 2009 1151 1157
4. S.E. Dorman, S. Goldberg, J.E. Stout, G. Muzanyi, J.L. Johnson, and M. Weiner Substitution of rifapentine for rifampin during intensive phase treatment of pulmonary tuberculosis: Study 29 of the Tuberculosis Trials Consortium J Infect Dis 206 2012 1030 1040
5. J.G. Chan, C.C. Duke, H.X. Ong, J.C. Chan, A.S. Tyne, and H.K. Chan A novel inhalable form of rifapentine J Pharm Sci 103 2014 1411 1421
6. I.M. Rosenthal, R. Tasneen, C.A. Peloquin, M. Zhang, D. Almeida, and K.E. Mdluli Dose-ranging comparison of rifampin and rifapentine in two pathologically distinct murine models of tuberculosis Antimicrob Agents Chemother 56 2012 4331 4340
7. K.E. Dooley, E.E. Bliven-Sizemore, M. Weiner, Y. Lu, E.L. Nuermberger, and W.C. Hubbard Safety and pharmacokinetics of escalating daily doses of the antituberculosis drug rifapentine in healthy volunteers Clin Pharmacol Ther 91 2012 881 888
8. H.S. Lee, H.C. Shin, S.S. Han, and J.K. Roh High-performance liquid chromatographic determination of rifapentine in serum using column switching J Chromatogr 574 1992 175 178
9. D.Z. D'Argenio, A. Schumitzky, and X. Wang ADAPT 5 user's guide: pharmacokinetic/pharmacodynamic systems analysis software. Biomedical Simulations Resource (BMSR) 2009 University of Southern California Los Angeles, CA
10. I.M. Rosenthal, M. Zhang, K.N. Williams, C.A. Peloquin, S. Tyagi, and A.A. Vernon Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model PLoS Med 4 2007 e344
11. P.V. Turner, T. Brabb, C. Pekow, and M.A. Vasbinder Administration of substances to laboratory animals: routes of administration and factors to consider J Am Assoc Lab Anim Sci 50 2011 600 613
12. M.E. Temple, and M.C. Nahata Rifapentine: its role in the treatment of tuberculosis Ann Pharmacother 33 1999 1203 1210
13. M. Gonzalez-Juarrero, L.K. Woolhiser, E. Brooks, M.A. DeGroote, and A.J. Lenaerts Mouse model for efficacy testing of antituberculosis agents via intrapulmonary delivery Antimicrob Agents Chemother 56 2012 3957 3959